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Abstract   
Background and Aims 
All oral direct-acting antivirals (DAAs) effectively treat chronic hepatitis C virus (HCV) 
infection, but the benefits in advanced liver disease are unclear. We compared 
outcomes in treated and untreated patients with decompensated cirrhosis. 
Methods 
Patients with HCV and decompensated cirrhosis or at risk of irreversible disease were 
treated in an Expanded Access Programme (EAP) in 2014. Treatment, by clinician 
choice, was with sofosbuvir, ledipasvir or daclatasvir, with or without ribavirin. For 
functional outcome comparison, untreated patients with HCV and decompensated 
cirrhosis who were registered on a database 6 months before treatment was available 
were retrospectively studied. Primary endpoint was sustained virological response 12 
weeks post antiviral treatment (treated cohort) and the secondary endpoint (both 
cohorts) was adverse outcomes (worsening in MELD score or serious adverse event) 
within 6 months. 
Results 
467 patients received treatment (409 decompensated cirrhosis). Viral clearance was 
achieved in 381 patients (81.6%) – 209 from 231 (90.5%) with genotype 1 and 132 from 
192 (68.8%) with genotype 3. MELD scores improved in treated patients (mean change 
-0.85) but worsened in untreated patients (mean + 0.75) (p<0.0001). Patients with initial 
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serum albumin <35 g/l, aged >65 or with low (<135 mmol/L) baseline serum sodium 
concentrations were least likely to benefit from therapy. 
Conclusions  
All oral DAAs effectively cured HCV in patients with advanced liver disease. Viral 
clearance was associated with improvement in liver function within 6 months compared 
to untreated patients. The longer term impact of HCV treatment in patients with 
decompensated cirrhosis remains to be determined. 
  
 
  
  
9 
 
Introduction 
All oral direct-acting antiviral (DAA) drugs for patients with chronic hepatitis C virus 
(HCV) infection have transformed treatment options. High response rates are observed 
in patients with compensated cirrhosis in clinical trials [1-4] and in real-life observational 
studies [5]. Even in patients with decompensated cirrhosis, for whom pegylated 
interferon is contraindicated and who otherwise have a poor prognosis, HCV can now 
be cured safely and effectively [6]. Experience of different DAA combinations in the real 
world is growing within a number of compassionate use programs [5,7]. However, 
virological response with all oral DAAs in decompensated cirrhosis, particularly in HCV 
genotype 3, is lower than in patients with less advanced liver disease [8,9]. Remaining 
uncertainties in treating such patients include the optimal duration of therapy, whether 
or not the regimen should include ribavirin, and what, if any, clinical benefits accrue to 
patients with such advanced liver disease following clearance of virus.  
Viral eradication in patients with chronic HCV infection has been shown to result in 
improvements in medium and long term outcomes – assessed both by patient reported 
quality of life measurements and mortality/morbidity [10-12]. However in patients with 
advanced, decompensated cirrhosis it is uncertain whether treatment and viral 
clearance is beneficial, and if meaningful functional hepatic recovery is possible. Clearly 
if treatment were able to reverse liver dysfunction and perhaps avoid the need for 
transplantation then therapy should be recommended.  However therapy, although 
generally safe, might be associated with adverse events, particularly in unstable 
patients with advanced cirrhosis [13] and may delay access to transplantation.  It is 
conceivable that patients with decompensated cirrhosis may eliminate virus, stabilise 
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their disease and not progress to a stage where transplantation is indicated. However, 
they may not recover to any meaningful extent and, post therapy, may be left without 
access to transplantation but with a poor quality of life (so called ‘MELD purgatory’). In 
the SOLAR study of patients with advanced liver disease infected with HCV genotypes 
1 and 4, viral eradication was rapidly associated with an improvement in severity of liver 
disease scores (MELD scores) [6] but no comparator group was included, and it is 
unclear whether benefits were related to viral clearance or to improved management of 
the patients in a clinical trial setting in specialist centres [1-3].  
Here we report on the outcomes of the NHS England Expanded Access Programme 
(EAP), which treated patients with severe liver disease of all viral genotypes, who were 
“at significant risk of death or irreversible damage within 12 months due to hepatic or 
extra-hepatic manifestations”. Sofosbuvir combined with the NS5A inhibitors ledipasvir 
or daclatasvir, with or without ribavirin, was used for a fixed duration of 12 weeks and 
patients were enrolled in the UK hepatitis C registry – HCV Research UK. To address 
the question of whether antiviral therapy is beneficial in unselected patients with 
decompensated cirrhosis infected with all HCV genotypes, we examined the functional 
outcomes of patients with equivalent disease stage, who enrolled into the same registry 
for at least 6 months prior to the start of EAP, and hence were not able to receive HCV 
treatment for at least 6 months of follow-up.  We show that HCV treatment improves 
outcomes and we present a model to predict those patients who are likely to derive 
most benefit from therapy. 
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Patients and Methods 
Study design and patients 
For treated patients this was a prospective, observational cohort study. Patients 
enrolled in the HCV Research UK registry who received antiviral therapy as part of the 
EAP between 1 April 2014 and 11 November 2014 were studied. Eligible patients were 
those at significant risk of death or irreversible damage from HCV infection within 12 
months, irrespective of genotype. Criteria for inclusion were decompensated cirrhosis - 
ascites, variceal bleed or encephalopathy (past or current), Child Pugh score ≥7, or 
non-hepatic manifestation of HCV likely to lead to irreversible damage in 12 months and 
intolerant to, or failed, pegylated interferon and ribavirin therapy, or exceptional 
circumstances (determined by a review panel). Treatment was chosen by the 
prescribing clinician and involved either ledipasvir/sofosbuvir or sofosbuvir/daclatasvir, 
both with or without ribavirin for a total of 12 weeks. Prescribing was restricted to 20 
English centres selected by NHS England in a competitive tender process, and 
comprised experienced HCV treatment centres. A criterion for participation in the bid 
was participation in HCV Research UK ensuring that data could be collected from all 
treatment sites. All patients receiving therapy were asked to consent to contribute 
anonymised data to the national registry, and those who agreed were included.  
For the comparator population (untreated) we used a retrospective, observational study 
design. Patients were selected from the HCV Research UK database. Inclusion criteria 
were decompensated cirrhosis (defined by the criteria above) who were enrolled before 
1 October 2013 (i.e. enrolled in the database 6 months before the EAP was initiated), 
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and patients subsequently included in the EAP who had been enrolled in the database 6 
months prior to the initiation of therapy.  
The study conforms to the ethical guidelines of the 1975 Declaration of Helsinki as 
reflected in a priori approval by the institution's human research committee. Ethics 
approval for HCV Research UK was given by NRES Committee East Midlands - Derby 
1 (Research Ethics Committee reference 11/EM/0314) and informed consent was 
obtained from each patient included in the study. Patients who declined to enrol in HCV 
Research UK were given antiviral therapy but data was not collected.  
Treatment 
All patients received a maximum of 12 weeks therapy. Sofosbuvir (400mg per day) was 
purchased from Gilead and clinicians chose to combine it with either ledipasvir (90mg 
per day), provided by Gilead as a single tablet co-formulation with sofosbuvir, or with 
daclatasvir (60mg per day, with dose adjustment to 30mg or 90mg per day as 
recommended in patients with relevant potential drug-drug interactions) which was 
provided by Bristol-Myers Squibb. Inclusion and dosage of ribavirin was discretionary 
according to the treating clinician.  
Monitoring 
Patients receiving therapy were reviewed at treatment weeks 2, 4, 8 and 12, and post 
treatment weeks 4 and 12. Clinical events were recorded on a standardised form and 
local accredited laboratories measured serum creatinine, bilirubin, albumin, alanine 
aminotransferase (ALT), sodium, HCV RNA level, full blood count and clotting profile, 
which were recorded for each study visit. Missing or late values during therapy were 
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ignored, and missing values from the initiation visit or week 12 post treatment visit were 
derived from the nearest adjacent test value taken before or after therapy respectively. 
MELD scores were calculated centrally using site-derived laboratory parameters.     
Serious adverse events, specifically any hospital admissions, decompensation events, 
liver transplantation, other complications of end-stage liver disease (including 
hepatocellular carcinoma) and death were recorded.  
Baseline demographic data (age, gender, ethnicity, body mass index (BMI), alcohol use, 
previous treatment history, decompensation events and HIV serostatus) and HCV 
genotype were taken from the original registration form recorded on the HCV Research 
UK database. 
Outcome measures  
The primary outcome was sustained virological response 12 weeks post treatment 
(SVR12) defined as undetectable HCV RNA measured at an accredited local laboratory 
with a lower limit of quantification (LLQ) of <30 IU/ml. Secondary outcomes included 
change in MELD score, and adverse clinical events during the study period. Overall 
adverse clinical outcome was defined as the composite of a MELD score increase by 2 
points or more, and/or occurrence of any serious adverse event. For patients who were 
enrolled in the comparator cohort, the responsible clinician reported the same events in 
a pre-defined form. 
All analyses were by intent to treat - patients who received a liver transplant during 
therapy who did not complete 12 weeks' therapy were regarded as having achieved 
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SVR12 if they had undetectable viral load at 24 weeks from start of treatment; subjects 
who were lost to follow up were regarded as treatment failures. 
Data analysis 
For the primary analysis (SVR12) comparisons were made using Chi-square. Predictors 
of relapse were also assessed using a logistic regression analysis in which only patients 
with a known virological outcome were included. Initially we used a univariable model, 
then all factors were included in a multivariable model, except for those that were likely 
to be highly collinear (i.e. Child Pugh score which was removed in favour of MELD 
score). 
For all functional outcomes analysis, patients were excluded if they were transplanted 
before treatment or if treatment was for an extra-hepatic indication. The proportion of 
patients with adverse clinical outcomes was determined and subsequently stratified by 
various baseline characteristics. The significance of any difference between the treated 
and comparison group were determined using Chi-squared tests. For calculations of 
MELD changes, we excluded patients who received a liver transplant during the study 
period, in order to evaluate MELD progression in patients with decompensated cirrhosis 
over 6 months with and without treatment. Similarly patients who died before study end, 
who did not have a MELD score at 6 months, were excluded from this analysis. The 
EAP and comparison cohort were then plotted in separate waterfall plots. We performed 
a sensitivity analysis excluding current alcohol users (of any number of units, within one 
month of study start date) to assess the potential impact of differences in alcohol use 
between the treated and untreated cohorts. Predictors of clinical benefit at baseline 
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(defined as a lack of serious adverse event and no increase in MELD score) was 
analysed using logistic regression. Predictors were assessed if they were determined a 
priori to plausibly influence outcome, including age, gender, body mass index, alcohol 
use (never, past or current), baseline MELD score, creatinine, albumin, platelets and 
sodium. The interactions between albumin and age, and baseline sodium, were also 
explored a priori. Internal validation was carried out using bootstrapping (50 iterations), 
with a 70% derivation sample. This generated a receiver-operating characteristic (ROC) 
curve, from which the area under the curve (AUC) was calculated. Model simplicity was 
prioritised, with additional factors only being accepted into the model if the AUC 
increased by more than 0.02. 
Data handling and statistical analysis were performed using STATA 13.1 with additional 
analysis performed using Orange 2.7.8. 
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Results 
Participants 
Treatment cohort 
A total of 480 patients received therapy as part of the EAP between the start of the 
programme (1 April 2014) to 11 November 2014; 467 patients consented to provide 
data to the HCV Research UK database (Figure 1).  At treatment initiation 409 (88%) 
patients had decompensated cirrhosis and/or Child Pugh score ≥7; 44 (9%) had 
undergone liver transplantation with aggressive HCV recurrence without 
decompensation. The remaining 14 (3%) patients were treated for extra-hepatic 
indications. Table 1 and Supplementary Table 1 show the baseline characteristics of the 
treated cohort. A higher proportion of genotype 3 patients received daclatasvir 
compared to genotype 1 (125/192 (65%) vs. 46/231(20%)), and clinicians chose to add 
ribavirin to the regimen for most (427/467 (91%)) patients (Table 2).  
 
Comparator cohort 
From the HCV Research UK database we identified 261 patients with decompensated 
HCV cirrhosis who fulfilled the criteria for inclusion in the study (Figure 1). Study start 
dates for these patients were between 5 October 2012 to 11 September 2014 and 177 
(68%) patients subsequently received antiviral therapy on the EAP after its initiation on 
1 April 2014. The treated and untreated cohorts had similar baseline characteristics and 
liver disease severity scores (Table 1). Amongst the comparator patients who did not 
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receive EAP therapy, there was a higher proportion of active alcohol users (23%) 
compared to those who subsequently received treatment (12.6%).  
Virological outcomes 
Sustained virological response (SVR12) was 381/467 (81.6%) overall for this population 
of patients with severe HCV disease at risk of death or irreversible harm within 12 
months (Table 2 and Figure 2). 51 patients (10.9%) responded but relapsed, 2 (0.43%) 
were non-responders, 17 (3.6%) died and 16 (3.4%) were lost to follow-up 
(Supplementary Table 2). Response was markedly influenced by genotype – SVR12 
was achieved in 209 of 231 (90.5%) patients infected with genotype 1 compared to 132 
of 192 (68.8%) patients with genotype 3 (p<0.0001). There was no statistically 
significant difference in response between ledipasvir- or daclatasvir-containing regimens 
in either genotype groups. SVR12 with ledipasvir/sofosbuvir and sofosbuvir plus 
daclatasvir, with or without ribavirin, was 91.9% (170/185) and 84.8% (39/46) 
respectively (p = 0.14) for genotype 1 infected patients, and 61.2% (41/67) and 72.8% 
(91/125) (p=0.098) for genotype 3 infected patients. The addition of ribavirin numerically 
increased response (352/427 (82.4%) versus 29/40 (72.5%), p=0.11).  
Of note, 19 patients had virus detectable at levels below the lower limit of quantification 
(LLQ, 30 IU/ml) after 12 weeks of therapy, and a further 4 patients “blipped” detectable 
virus below LLQ at 16 weeks (i.e. 4 weeks after end of therapy). 22 of these 23 patients 
subsequently achieved SVR12, including all 4 of the latter group. 
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We examined baseline factors that might predict virological failure (Supplementary 
Table 3). In this analysis we included only patients with documented virological failure 
and by multivariable analysis, genotype 3 (OR=10.3, 95% CI 4.4-24.6), BMI >30 kg/m2 
(OR=2.9, CI 1.1-8.2) and detectable virus at treatment week 2 (OR=2.6, CI 1.1-6.3) 
were significantly associated with virological failure. The impact of detectable week 2 
viral load was greater in patients with genotype 3 than genotype 1. For patients with 
genotype 3 HCV, virological failure in those with and without detectable virus at 
treatment week 2 was 32/105 (30.5%) and 7/70 (10.0%) respectively (p=0.00143). For 
those with genotype 1 HCV, virological failure in patients with detectable virus at week 2 
was 8/141 (5.7%) compared to 4/79 (5.1%) in patients with undetectable virus (p=0.84). 
Therapy without ribavirin (OR=9.0, CI 2.5-31.0) and therapy with ledipasvir compared to 
daclatasvir (OR = 2.7 CI 1.2-6.3) were also significantly associated with virological 
failure, although this latter finding was likely driven by the differential response in 
patients with genotype 3 infection, which showed numerical advantage with daclatasvir 
over ledipasvir.  
Treatment safety  
Treatment with sofosbuvir and an NS5A inhibitor in this patient group with advanced 
liver disease and/or complex extrahepatic complications was well tolerated. Serious 
adverse events comprised mainly complications of end-stage liver disease 
(Supplementary Table 4). Twenty six patients (5.6%) discontinued treatment 
prematurely, including 7 who died on treatment. Most patients (306/427) treated with 
ribavirin received the recommended dose of 1.2g per day for patients weighing > 75 kg 
and 1 g per day for others, 18.7% of patients receiving ribavirin required dose 
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reductions and 9.6% discontinued ribavirin. The median ribavirin dose was 1g per day. 
There were only 8 patients with baseline haemoglobin (Hb) below 80 g/L, all but one 
had ribavirin omitted from their regimen. Grade 3/4 anaemia (Hb ≤ 80 g/L) occurred in 
23 (5.4%) patients receiving ribavirin. Development of acute kidney injury on treatment 
(defined as creatinine increase of 1.5-fold or higher at treatment week 12 compared to 
baseline) was infrequent, occurring in 13/467 (2.8%) patients.  
Functional outcomes 
We examined only patients with decompensated cirrhosis and/or Child Pugh score B or 
worse in this analysis (n=409). Liver function over a 6 month period (3 months on 
therapy and 3 months post therapy) was compared to the untreated cohort. Figure 3 
and Supplementary Table 5 show MELD score changes and development of adverse 
clinical outcomes within the two cohorts. Treated patients had a mean negative change 
in MELD (-0.85, SD 2.54) representing improvement in liver function, whereas untreated 
patients had a mean positive change (0.75, SD 3.54) representing worsening in liver 
function (p<0.0001). Significantly fewer treated patients developed a profound 
worsening in MELD (increase of 2 points or more) over 6 months compared to untreated 
patients (23.0% vs 37.9%, p=0.05). The proportion of patients with at least one 
decompensating event during the study period was reduced in the treated compared to 
untreated cohort, apart from the subgroup with baseline MELD score >14. Rates of new 
decompensation (i.e. development of decompensating event(s) in a patient with 
recompensated disease at baseline) were significantly lower in the treated cohort (3.7% 
versus 10.0%, p = 0.0009) compared to the untreated cohort.  There were no significant 
differences between treated and untreated patients in the incidence of hepatocellular 
  
20 
 
carcinoma, sepsis or death. Overall adverse clinical outcomes (composite of MELD 
worsening by 2 or more and/or any serious adverse event) were 52.3% in the treated 
group and 63.6% in the untreated group (p=0.004).  
For treated patients, SVR12 status did not predict MELD score change. However, a 
smaller proportion of patients who achieve SVR12 had an increase in MELD score ≥2 
compared to those who did not achieve SVR12 (11.9% versus 68.8%). Adverse 
outcomes for patients with and without SVR12 were 45.0% and 82.5% (Supplementary 
Table 5). 
To determine whether or not alcohol consumption (which differed in the treated and 
untreated populations) impacted outcomes, we analysed functional response after 
excluding patients who were active alcohol users (of any amount) at baseline 
(Supplementary table 6). Among patients who were past or never users of alcohol, 
greater extents of improvement were observe in those who received treatment than 
untreated patients (mean change in MELD score -0.86 versus 0.68; composite adverse 
outcome in 52.0% versus 61.7%). 
Overall adverse outcomes were more frequent in patients with high baseline MELD and 
low albumin (≤35g/L) for both treated and untreated groups (Supplementary Table 5). 
For patients with decompensated cirrhosis, we assessed whether baseline 
characteristics might be useful in predicting functional benefit gained from therapy. We 
defined functional benefit as no MELD score worsening and no development of serious 
adverse events following treatment. Patients older than 65 years with reduced synthetic 
function (serum albumin ≤35 g/L) had the lowest odds of deriving functional benefit with 
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antiviral treatment (Table 3). However the model was not robust with a ROC area under 
the curve of 0.5484 (Supplementary Figure 1). Alternatively, using baseline sodium level 
with a cut-off at 135 mmol/L increases the AUC to 0.5797 (Supplementary Figure 2). 
We did not study the interaction of all three factors due to insufficient number of patients 
within the subgroups.  
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Discussion 
The efficacy of all-oral antiviral regimens in the management of patients with 
compensated liver disease due to chronic HCV infection is now established [1-4]  and 
data on patients with decompensated cirrhosis are emerging [5-7,14]. In this study we 
examined a fixed, 12 week, duration course of antiviral therapy in a large 
heterogeneous group of patients with decompensated cirrhosis or life-threatening 
complications of HCV infection, and we compared outcomes to an untreated cohort with 
equivalent disease and duration of follow up.  
The EAP study was robustly conducted with prospective, standardised monitoring and 
reporting through a central database - HCV Research UK. The majority of treated 
patients were included in this report (only 13 patients declined to participate) thus 
reflecting a true 'real-life' cohort, and a large number of patients infected with genotype 
3 were included for the first time. The inclusion criteria for EAP treatment was patients 
with significant risk of death or irreversible harm within 12 months, mostly with 
decompensated cirrhosis. Markers of liver disease severity such as MELD score and 
platelet count were similar to other studies of HCV treatment in decompensated patients 
(SOLAR-1, ASTRAL-4) [6, 14]. Within the decompensated subgroup, 17% patients were 
Child Pugh class A at baseline, but had past decompensation events, and therefore 
remained at significant risk from severe liver disease. Importantly for the comparator 
group we selected patients who enrolled in the cohort before therapy was available, 
thereby reducing the inherent bias in selecting treated patients with prior follow up.  
We noted excellent virological response rates in patients infected with genotype 1 HCV 
regardless of choice of NS5A inhibitor, but response was statistically significantly lower 
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in patients with genotype 3 HCV.  In this non-randomised study SVR was numerically 
higher in patients with genotype 3 infection who received daclatasvir compared to 
ledipasvir, although the clinical relevance of this observation is not addressed in this 
study.    
Aside from treatment regimen, we found the presence of detectable HCV RNA at 
treatment week 2 was an independent predictor of virological failure, and was a stronger 
predictor than previous treatment history or markers of severe liver disease such as 
high MELD score or thrombocytopenia. This finding is novel to other analyses of 
treatment response evaluating only genotype 1 patients with less advanced cirrhosis 
[15] and was most marked in patients with genotype 3 infection. On-treatment viral 
response may help to guide the need for extension to 24 weeks of therapy in patients 
with a lower likelihood of a clinical response, specifically patients with genotype 3 
infection.  
The beneficial role of ribavirin in treating patients with decompensated cirrhosis is 
suggested by improved virological response rates in ribavirin-containing regimens 
(whether combined with ledipasvir or daclatasvir), particularly for patients infected with 
genotype 3. However the total number of patients treated without ribavirin was small 
and although no clear adverse events were associated with ribavirin, robust conclusions 
cannot be drawn.  While the clinical trial of ledipasvir/sofosbuvir in patients with 
decompensated cirrhosis did not include a ribavirin-free arm (SOLAR-1), in ASTRAL-4 
which treated 267 patients infected with genotypes 1 to 6 and decompensated cirrhosis 
with 12 weeks of sofosbuvir and velpatasvir, with or without ribavirin, and 24 weeks of 
sofosbuvir and velpatasvir alone, ribavirin showed a clear advantage. The study was not 
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powered to detect significance between the three treatment groups, but the addition of 
ribavirin increased SVR, and to a greater extent than the 24 week duration, particularly 
in genotype 3 infected patients. [14] 
Not unexpectedly from this population with advanced disease, serious adverse events 
were common, comprising mainly events related to end-stage liver disease. However, 
treatment was well tolerated with few premature discontinuations.  
To assess the impact of antiviral treatment in decompensated cirrhosis, we selected a 
comparator cohort from patients registered in the national database HCV Research UK 
who had decompensation, and retrospectively monitored the change in MELD scores 
and development of serious adverse events over a 6 month period. Patients from both 
treatment and comparator cohorts were selected from the same network of experienced 
HCV treatment centres, thus reducing the impact of ‘improved care’ in patients receiving 
antiviral therapy. Amongst treated patients a greater proportion showed an improvement 
in MELD scores, and for patients who had worsened MELD the degree of worsening 
was less compared to untreated patients, suggesting benefits of therapy within 6 
months. This was observed even for patients who failed treatment (mean MELD change 
-0.63), who nevertheless experienced several months of non-viraemia prior to relapse. 
We studied a composite endpoint of MELD worsening and development of any serious 
adverse events, rather than limiting to liver-related events, which we felt was the most 
clinically useful endpoint. Treated patients had significantly fewer adverse outcomes, 
with MELD score change and number of decompensation events being the main 
contribution to the outcome difference, while liver cancers, transplants and deaths were 
not significantly different over this 6 month period. Treated patients who achieved 
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SVR12 had considerably better functional outcomes than those who were treated but 
failed to achieve SVR12 (adverse outcomes 45.0% and 82.5% respectively).  
This study was not a randomised controlled trial of treatment versus no treatment, which 
would be unethical. Wherever possible we attempted to reduce biases in the untreated 
comparison population. Patients were selected from the HCV Research UK database 
prior to treatment becoming available. Whilst this population may contain patients who 
were not treated subsequently because they died or deteriorated to a stage where 
treatment could not be considered, it also contains patients who survived and were fit 
enough to receive treatment through the EAP. By using the entire available ‘pre-EAP’ 
population, we reduced the possibility of selecting only patients who were fit enough to 
receive antiviral therapy and we minimised bias.  It is possible that differences in 
severity of liver disease remained between the treated and untreated groups, but these 
were not evident at baseline measurements, with the exception of alcohol consumption 
which was greater in the comparator cohort.  As this may have contributed to the 
increased adverse outcomes in the untreated population, we performed a post-hoc 
analysis excluding active alcohol users in both groups, and found a similar improvement 
in MELD in treated patients, worsening in MELD and increased adverse outcomes for 
untreated patients. Monitoring of the untreated group was retrospective but was 
prospective for the treated group, which might bias the study towards a relative under-
reporting of events within the comparator cohort.  
Finally we attempted to develop a prediction model for functional outcomes after 
antiviral treatment to identify patients most likely to benefit from therapy. Regression 
analysis of baseline characteristics and association with MELD change yielded baseline 
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MELD score as the only significant independent factor. We combined age and serum 
albumin data and found older patients with poor synthetic function to have a 
substantially lower chance of benefit compared to younger patients with preserved 
synthetic function (39.3% vs 60.5%, p=0.050). Given the importance of sodium as a 
variable in predicting mortality risk in addition to MELD score, we analysed the odds 
ratio of benefit at a cut-off of 135 mmol/L and showed that patients with normal range 
sodium levels to have higher chance of treatment benefit than patients with 
hyponatraemia (51.1% vs 39.1%, p=0.023). This model did not show sufficient 
discrimination to allow it to be used to recommend that treatment should be withheld nor 
is it robust enough to recommend that a patient proceed with liver transplantation, if 
appropriate. However, given that interferon-free therapy has opened up treatment 
options for vulnerable patients, the risk estimates provided within the modelling may 
help clinicians when they discuss the risks and benefits of all oral treatment with 
patients. Reports of decompensation on DAA therapy for patients with advanced 
cirrhosis [13] reiterates the importance of such discussions and the need for a careful 
evaluation of the different options on a case by case basis. 
 
In summary, this is a large real-life study of all-oral HCV therapy in patients with 
advanced HCV disease with a significant risk of death or irreversible damage within 12 
months. Overall virological response was high and we found early improvement in liver 
parameters and in clinical outcomes after antiviral treatment, compared to untreated 
patients. The longer term benefits of therapy in patients with decompensated disease 
remain to be ascertained.  
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Figures 
 
Figure 1. Derivation of treated and comparator patient cohorts. 
Figure 2. Sustained virological response rates at 12 weeks post therapy for 
patients with decompensated cirrhosis. Error bars represent 95% confidence 
intervals. 
Figure 3. Changes in MELD score over 6 months in treated (upper panel) and 
untreated (lower panel) patients who survived for the duration of follow up.  
Patients who did not achieve an SVR are highlighted in pale grey and patients who died 
(n=32) and thereby could not achieve a second MELD assessment were excluded 
 
  
  
31 
 
* DAA = with protease inhibitors boceprevir/telaprevir 
Table 1. Baseline characteristics of treated and comparator (untreated) patients.  
  Treated Cohort Untreated Cohort 
Characteristic All (%) Decompensated 
Baseline 
liver 
transplant 
Extra 
hepatic 
indication 
Total (%) 
Total patients 467 409 44 14 261 
Age (years) median 54 (28-80) 54 (28-79) 62 (32-75) 58 (35-80) 54 (33-77) 
Gender Male 339 (72.6%) 297 35 7 214 (82.0%) 
Ethnicity Caucasian 347 (74.3%) 302 34 11 230 (88.1%) 
Prior therapy Yes 284 (60.8%) 244 33 7 162 (62.1%) 
  with DAA* 17 (3.6%) 14 3 0   
HIV infected Yes 23 (4.9%) 20 2 1 6 (2.3%) 
Virology   
   
  
 
  
Genotype 1 231 (49.3%) 200 26 5 129 (49.4%) 
 3 192 (41.1%) 172 14 6 90 (34.5%) 
 Other 44 (9.4%) 37 4 3 42 (16.1%) 
Viral load (iu/mL) 
 
median 
 
280511 
 
255279.5 
 
1006189 
 
2091786 
 
208688 
range (17-17835823) (17-13613875) 
(71.5-
17835823) 
 (2189-
7838385) 
(80-23100000) 
Liver/renal status            
  
Bilirubin (µmol/L) median, range 27   (4-433) 
 
28 (4-433) 18 (5-82) 14 (5-30) 26 (3-335) 
Albumin (g/L) 31   (17-55) 31 (17-55) 35 (23-48) 36 (29-46) 32 (10-46) 
MELD 
 
11   (6-32) 12 (7-32) 11 (6-25) 10 (6-15) 11 (6-32) 
Creatinine (µmol/L) 69   (32-477) 66 (32-477) 98 (60-286) 75 (48-206) 68 (25-340) 
ALT (U/L) 
 
53   (8-594) 54 (8-345) 44 (17-594) 48 (24-156) 
  
Platelets (x10^9/L) 74   (3-321) 72 (20-277) 116 (3-321) 114 (17-233) 70 (3-358) 
 
  
   
  
  
Child Pugh Score 
 
B      n (%) 
 
319 (68.3) 
 
297 (72.6) 
 
21 (47.7) 
 
0 (0.0)   
  C 43 (9.2) 41 (10.0) 2 (45.5) 0 (0.0) 
  
Ascites Present 197 (42.2) 183 (44.7) 14 (31.8) 0 (0.0)     
Alcohol use Current 59 (12.6%) 53 3 3 60 (23.0%) 
  Never 95 (20.3%) 80 10 5 53 (20.3%) 
  Past 281 (60.2%) 246 31 4 135 (51.7%) 
  Unknown 32 (6.9%) 30 0 2 13 (5.0%) 
Treatment Sof/DCV 15 (3.2%) 12 1 2 
 
  
  Sof/DCV/RBV 172 (36.8%) 150 17 5 
 
  
  Sof/LDV 25 (5.4%) 18 7 0 
 
  
  Sof/LDV/RBV 255 (54.6%) 229 19 7     
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 Treatment 
regimen 
All patients (n=467) 
 Decompensated 
patients (n=409) 
OLT before baseline 
(n=44) 
Extrahepatic 
patients (n=14) 
    SVR12 n %  SVR12 n % SVR12 n % SVR12 n % 
All patients All 381 467 81.6  329 409 80.4 38 44 86.4 14 14 100.0 
  Sof/DCV 11 15 73.3  8 12 66.7 1 1 100.0 2 2 100.0 
  Sof/DCV/RBV 133 172 77.3  114 150 76.0 14 17 82.4 5 5 100.0 
  Sof/LDV 18 25 72.0  13 18 72.2 5 7 71.4 0 0 - 
  Sof/LDV/RBV 219 255 85.9  194 229 84.7 18 19 94.7 7 7 100.0 
Genotype 1 All 209 231 90.5  179 200 89.5 25 26 96.2 5 5 100.0 
  Sof/DCV 3 5 60.0  2 4 50.0 1 1 100.0 0 0 - 
  Sof/DCV/RBV 36 41 87.8  30 34 88.2 5 6 83.3 1 1 100.0 
  Sof/LDV 16 18 88.9  11 13 84.6 5 5 100.0 0 0 - 
  Sof/LDV/RBV 154 167 92.2  136 149 91.3 14 14 100.0 4 4 100.0 
Genotype 3 All 132 192 68.8  117 172 68.0 9 14 64.7 6 6 100.0 
  Sof/DCV 5 7 71.4  3 5 60.0 0 0 - 2 2 100.0 
  Sof/DCV/RBV 86 118 72.9  75 105 71.4 8 10 80.0 3 3 100.0 
  Sof/LDV 2 7 28.6  2 5 40.0 0 2 0.0 0 0 - 
  Sof/LDV/RBV 39 60 65.0  37 57 64.9 1 2 50.0 1 1 100.0 
Other All 40 44 90.9  33 37 89.2 4 4 100.0 3 3 100.0 
  Sof/DCV 3 3 100.0  3 3 100.0 0 0 - 0 0 - 
  Sof/DCV/RBV 11 13 84.6  9 11 81.8 1 1 100.0 1 1 100.0 
  Sof/LDV - 0 -  0 0 - 0 0 - 0 0 - 
  Sof/LDV/RBV 26 28 92.8  21 23 91.3 3 3 100.0 2 2 100.0 
 
Table 2. Choice of treatment regimens according to HCV genotypes and virological 
response at 12 weeks post-treatment (SVR12) in patients treated on the Expanded 
Access Programme 
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Adverse 
outcome 
(n) 
Benefit 
(n) 
Benefit 
 
Odds 
ratio 95% CI 
Age / albumin (g/L) 
interaction terms Age <65 Albumin ≥35 34 52 60.5 1 (Ref) 
  
 
Age <65 Albumin <35 159 124 43.8 0.52 0.32 0.86 
 
Age ≥65 Albumin ≥35 6 6 50.0 0.67 0.20 2.27 
  Age ≥65 Albumin <35 17 11 39.3 0.44 0.18 1.05 
Baseline serum 
sodium  ≥135   135 141 51.1 1 (Ref) 
  (mmol/L) <135   81 52 39.1 0.63 0.41 0.97 
 
 
Table 3. Likelihood of functional benefit (no MELD increase and no serious adverse 
events) or adverse outcome (MELD increase and/or serious adverse events) following 
antiviral therapy based on patient baseline characteristics 
 
 
  
 
Patients who started treatment in the NHS England 
Early Access Programme since 1 April 2014 
N = 806 
Patients with a recorded 
start of treatment before 
11 November 2014 
N = 480 
EAP Study Cohort 
N = 467 
Ineligible (i.e. prisoner) 
or refused consent to 
join HCV Research UK 
N = 13 
Patients enrolled into Hepatitis C Research UK before  
1 October 2013 
N ~10,000 
Enrolment liver disease status = decompensated 
cirrhosis, with no prior liver transplant and currently 
viraemic  
N = 261 
Subsequently treated in 
EAP after 1 April 2014 
N = 177 
No record of subsequent 
treatment within EAP 
N = 84 
Comparator cohort followed up untreated 
for 6 months 
N = 261 
SVR12 
N = 381 
Virological failure 
N = 53 
Died  
N = 17 
Lost to follow-up 
N = 16 
Died 
N = 15 
  
 
 
All treatment durations = 12 weeks 
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